|
Name |
Andrastin C
|
Molecular Formula | C28H40O6 | |
IUPAC Name* |
methyl (3S,5S,8S,9S,10R,13R,14R)-3-acetyloxy-17-hydroxy-4,4,8,10,12,13,16-heptamethyl-15-oxo-2,3,5,6,7,9-hexahydro-1H-cyclopenta[a]phenanthrene-14-carboxylate
|
|
SMILES |
CC1=C[C@H]2[C@@]3(CC[C@@H](C([C@H]3CC[C@@]2([C@]4([C@@]1(C(=C(C4=O)C)O)C)C(=O)OC)C)(C)C)OC(=O)C)C
|
|
InChI |
InChI=1S/C28H40O6/c1-15-14-19-25(6)12-11-20(34-17(3)29)24(4,5)18(25)10-13-26(19,7)28(23(32)33-9)22(31)16(2)21(30)27(15,28)8/h14,18-20,30H,10-13H2,1-9H3/t18-,19+,20+,25-,26+,27+,28-/m1/s1
|
|
InChIKey |
AWMJEDMVXAOTQZ-QUQNHZJXSA-N
|
|
Synonyms |
Andrastin C; DTXSID20894024; CHEBI:142867; methyl (3beta,5beta,8alpha,9beta,10alpha,13alpha)-3-(acetyloxy)-15-hydroxy-4,4,8,12,16-pentamethyl-17-oxoandrosta-11,15-diene-14-carboxylate; methyl (3S,5S,8S,9S,10R,13R,14R)-3-acetyloxy-17-hydroxy-4,4,8,10,12,13,16-heptamethyl-15-oxo-2,3,5,6,7,9-hexahydro-1H-cyclopenta[a]phenanthrene-14-carboxylate; methyl 3beta-(acetyloxy)-15-hydroxy-4,4,8alpha,12,16-pentamethyl-17-oxo-5beta,9beta,10alpha,13alpha-androsta-11,15-diene-14-carboxylate
|
|
CAS | NA | |
PubChem CID | 9982260 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 472.6 | ALogp: | 5.2 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 89.9 | Aromatic Rings: | 4 |
Heavy Atoms: | 34 | QED Weighted: | 0.321 |
Caco-2 Permeability: | -4.939 | MDCK Permeability: | 0.00001570 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.785 |
30% Bioavailability (F30%): | 0.893 |
Blood-Brain-Barrier Penetration (BBB): | 0.874 | Plasma Protein Binding (PPB): | 70.24% |
Volume Distribution (VD): | 0.658 | Fu: | 28.74% |
CYP1A2-inhibitor: | 0.014 | CYP1A2-substrate: | 0.663 |
CYP2C19-inhibitor: | 0.063 | CYP2C19-substrate: | 0.889 |
CYP2C9-inhibitor: | 0.155 | CYP2C9-substrate: | 0.053 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.098 |
CYP3A4-inhibitor: | 0.731 | CYP3A4-substrate: | 0.824 |
Clearance (CL): | 6.586 | Half-life (T1/2): | 0.217 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.193 |
Drug-inuced Liver Injury (DILI): | 0.709 | AMES Toxicity: | 0.036 |
Rat Oral Acute Toxicity: | 0.792 | Maximum Recommended Daily Dose: | 0.436 |
Skin Sensitization: | 0.06 | Carcinogencity: | 0.605 |
Eye Corrosion: | 0.99 | Eye Irritation: | 0.408 |
Respiratory Toxicity: | 0.973 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002012 | 0.828 | D0H2MO | 0.296 | ||||
ENC004115 | 0.812 | D0V2JK | 0.294 | ||||
ENC002033 | 0.717 | D04GJN | 0.287 | ||||
ENC003138 | 0.673 | D0X7XG | 0.279 | ||||
ENC005963 | 0.649 | D0X4RS | 0.273 | ||||
ENC003457 | 0.631 | D03MTN | 0.270 | ||||
ENC005965 | 0.605 | D02CNR | 0.267 | ||||
ENC005964 | 0.561 | D02CJX | 0.262 | ||||
ENC001980 | 0.415 | D06AEO | 0.260 | ||||
ENC001833 | 0.392 | D0I2SD | 0.256 |